Associations - lapatinib

HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	lapatinib Sensitive: A1 - Approval lapatinib Sensitive : A1	lapatinib Sensitive: A1 - Approval lapatinib Sensitive : A1
HER-2 overexpression	Hormone Receptor Negative Breast Cancer	HER-2 overexpression	Hormone Receptor Negative Breast Cancer	trastuzumab + lapatinib Sensitive: A1 - Approval trastuzumab + lapatinib Sensitive : A1	trastuzumab + lapatinib Sensitive: A1 - Approval trastuzumab + lapatinib Sensitive : A1
HER-2 overexpression	Breast Cancer	HER-2 overexpression	Breast Cancer	lapatinib Sensitive: A1 - Approval lapatinib Sensitive : A1	lapatinib Sensitive: A1 - Approval lapatinib Sensitive : A1
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2
EGFR expression	Chordoma	EGFR expression	Chordoma	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2
HER-2 amplification	Colorectal Cancer	HER-2 amplification	Colorectal Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
No biomarker	Ependymoma	No biomarker	Ependymoma	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	trastuzumab + lapatinib Resistant: B - Late Trials trastuzumab + lapatinib Resistant : B	trastuzumab + lapatinib Resistant: B - Late Trials trastuzumab + lapatinib Resistant : B
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	lapatinib Resistant: B - Late Trials lapatinib Resistant : B	lapatinib Resistant: B - Late Trials lapatinib Resistant : B
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B
HER-2 expression	Cholangiocarcinoma	HER-2 expression	Cholangiocarcinoma	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	lapatinib Sensitive: B - Late Trials lapatinib Sensitive : B	lapatinib Sensitive: B - Late Trials lapatinib Sensitive : B
HER-2 amplification	Gastric Cancer	HER-2 amplification	Gastric Cancer	lapatinib Sensitive: B - Late Trials lapatinib Sensitive : B	lapatinib Sensitive: B - Late Trials lapatinib Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	lapatinib Resistant: B - Late Trials lapatinib Resistant : B	lapatinib Resistant: B - Late Trials lapatinib Resistant : B
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	lapatinib Sensitive: B - Late Trials lapatinib Sensitive : B	lapatinib Sensitive: B - Late Trials lapatinib Sensitive : B
HR positive + HER-2 positive	Hormone Receptor Positive Breast Cancer	HR positive + HER-2 positive	Hormone Receptor Positive Breast Cancer	Aromatase inhibitor + trastuzumab + lapatinib Sensitive: B - Late Trials Aromatase inhibitor + trastuzumab + lapatinib Sensitive : B	Aromatase inhibitor + trastuzumab + lapatinib Sensitive: B - Late Trials Aromatase inhibitor + trastuzumab + lapatinib Sensitive : B
PIK3CA mutation + HR positive	HER2 Positive Breast Cancer	PIK3CA mutation + HR positive	HER2 Positive Breast Cancer	trastuzumab + lapatinib Resistant: B - Late Trials trastuzumab + lapatinib Resistant : B	trastuzumab + lapatinib Resistant: B - Late Trials trastuzumab + lapatinib Resistant : B
HER-2 overexpression	Cholangiocarcinoma	HER-2 overexpression	Cholangiocarcinoma	lapatinib Sensitive: C1 - Off-label lapatinib Sensitive : C1	lapatinib Sensitive: C1 - Off-label lapatinib Sensitive : C1
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2
EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2
HER-2 expression	Breast Cancer	HER-2 expression	Breast Cancer	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2
ERBB4 mutation	Melanoma	ERBB4 mutation	Melanoma	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2
HER-2 G766V	Non Small Cell Lung Cancer	HER-2 G766V	Non Small Cell Lung Cancer	lapatinib + pyrotinib Sensitive: C3 – Early Trials lapatinib + pyrotinib Sensitive : C3	lapatinib + pyrotinib Sensitive: C3 – Early Trials lapatinib + pyrotinib Sensitive : C3
CDK12 amplification	HER2 Positive Breast Cancer	CDK12 amplification	HER2 Positive Breast Cancer	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3

lapatinib

Associations
(107)

Associations
(107)

lapatinib

Associations(107)

Associations(107)

Associations
(107)

Associations
(107)